Drug Type Monoclonal antibody |
Synonyms RO7790121 |
Target |
Action- |
Mechanism VEGI modulators(Tumor necrosis factor superfamily member 15 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ulcerative colitis, active severe | Phase 3 | United States | 07 Nov 2024 | |
Ulcerative colitis, active severe | Phase 3 | China | 07 Nov 2024 | |
Ulcerative colitis, active moderate | Phase 3 | Belgium | 17 Sep 2024 | |
Ulcerative colitis, active moderate | Phase 3 | Portugal | 17 Sep 2024 | |
Crohn Disease | Phase 2 | United States | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | Belgium | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | Bulgaria | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | Canada | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | France | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | Germany | - | 24 Jul 2023 |